ArticleDialogues in clinical neuroscience2011
Pharmacogenomics of antidepressant treatment effects.
Article in Dialogues in clinical neuroscience, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03907124 (Clinical Utility of Pharmacogenomics of Psychotropic Medications), which is not on this map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Utility of Pharmacogenomics of Psychotropic Medications
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pharmacogenomic scores in psychiatry: systematic review of current evidence.Translational psychiatry · 2024Pooled it
- Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.Ontario health technology assessment series · 2021Pooled it
- Article
- Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare.Pharmaceutics · 2024Review
- Research on treatment-related aspects of depression from India in the preceding decade (2014-2023): An updated systematic review.Indian journal of psychiatry · 2023Review
- Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression.Advances in experimental medicine and biology · 2021Article
- Pharmacogenomics for Primary Care: An Overview.Genes · 2020Review
- A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2018Article
- Optimization of Antidepressant use with Pharmacogenetic Strategies.Current genomics · 2017Article
- Treatment-resistant depression: are animal models of depression fit for purpose?Psychopharmacology · 2015Review
- Clinical Utility of Combinatorial Pharmacogenomics-Guided Antidepressant Therapy: Evidence from Three Clinical Studies.Molecular neuropsychiatry · 2015Article
- Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.The pharmacogenomics journal · 2015Article
- Blood transcriptomic biomarkers in adult primary care patients with major depressive disorder undergoing cognitive behavioral therapy.Translational psychiatry · 2014Article
- Launching the 'war on mental illness'.Molecular psychiatry · 2014Article
- A systematic review and meta-analysis of trials of treatment of depression from India.Indian journal of psychiatry · 2014Article
- The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder.European archives of psychiatry and clinical neuroscience · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There has been considerable promise and hope that pharmacogenomics will optimize existing treatments for major depression, as well as identify novel targets for drug discovery. Immediately after the sequencing of the human genome, there was much hope that tremendous progress in pharmacogenomics would rapidly be achieved. In the past 10 years this initial enthusiasm has been replaced by a more sober optimism, as we have gone a long way towards the goal of guiding therapeutics based on genomics. While the effort to translate discovery to clinical applications is ongoing, we now have a vast body of knowledge as well as a clear direction forward. This article will provide a critical appraisal of the state of the art in the pharmacogenomics of depression, both in terms of pharmacodynamics and pharmacokinetics.
Indexed as
Identifiers
21485747PMC3181965What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.